The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
from the insulinogenic index (IGI) and the insulin sensitivity index (ISIcomposite). The fasting-based disposition index (SPINA-DI) can be obtained from the product of the secretory capacity of pancreatic beta cells (
=== Grafting polymers onto and/or from surfaces === Antimicrobial activity can be imparted onto a surface through the grafting of functionalized polymers, for example, those terminated with quaternary amine functional groups, through one of two principle methods. With these methods—"grafting to" and "grafting from"—polymers can be chemically bound to a solid surface and thus the properties of the surface (i.e. antimicrobial activity) can be controlled. Quaternary ammonium ion-containing polymers (PQA) have been proven to effectively kill cells and spores through their interactions with cell membranes. A wealth of nitrogenous monomers can be quaternized to be biologically active. These monomers, for example 2-dimethylaminoethyl methacrylate (DMAEMA) or 4-vinyl pyridine (4-VP) can be subsequently polymerized with ATRP. Thus antimicrobial surfaces can be prepared via "grafting to" or "grafting from" mechanisms.
=== Wet chemistry === Nanoparticles of certain materials can be created by "wet" chemical processes, in which solutions of suitable compounds are mixed or otherwise treated to form an insoluble precipitate of the desired material. The size of the particles of the latter is adjusted by choosing the concentration of the reagents and the temperature of the solutions, and through the addition of suitable inert agents that affect the viscosity and diffusion rate of the liquid. With different parameters, the same general process may yield other nanoscale structures of the same material, such as aerogels and other porous networks. The nanoparticles formed by this method are then separated from the solvent and soluble byproducts of the reaction by a combination of evaporation, sedimentation, centrifugation, washing, and filtration. Alternatively, if the particles are meant to be deposited on the surface of some solid substrate, the starting solutions can be by coated on that surface by dipping or spin-coating, and the reaction can be carried out in place. Electroless deposition provides a unique opportunity for growing nanoparticles onto surface without the need for costly spin coating, electrodeposition, or physical vapor deposition. Electroless deposition processes can form colloid suspensions catalytic metal or metal oxide deposition. The suspension of nanoparticles that result from this process is an example of colloid. Typical instances of this method are the production of metal oxide or hydroxide nanoparticles by hydrolysis of metal alkoxides and chlorides.
Antiviral proteins are proteins that are induced by human or animal cells to interfere with viral replication. These proteins are isolated to inhibit the virus from replicating in a host's cells and stop it from spreading to other cells. The Pokeweed antiviral protein and the Zinc-Finger antiviral protein are two major antiviral proteins that have undergone several tests for viruses, including HIV and influenza.
Sources: en.wikipedia.org
=== Change upon heating === When heated, ovalbumin undergoes a conformational change from its soluble, serpin structure into an insoluble all-β-sheet structure with exposed hydrophobic regions. This causes the protein to aggregate and cause the solidification associated with cooked egg white.
== Ecology == Xanthoria parietina demonstrates a range of physiological and morphological adaptations that facilitate its survival in diverse habitats. Populations in drier, more exposed habitats produce longer-chain surface hydrocarbons (alkanes), whereas those in more humid, cooler regions synthesize shorter-chain alkanes—a response that helps reduce water loss, similar to adaptations seen in vascular plants. Its thallus morphology is plastic; forms in moist stream beds tend to be semi-erect and orange-yellow, whereas those in drier, sun-exposed sites are more compact and darker orange. These differences appear to be induced by environment conditions rather than genetic differences.
== History == DOM was the first psychedelic of the DOx series to be discovered. It was first synthesized by Alexander Shulgin at Dow Chemical Company in 1963, who had had his first psychedelic experience, with mescaline (3,4,5-trimethoxyphenethylamine), in 1960. Shulgin personally tried DOM on January 4, 1964 and discovered its psychedelic effects. 2,4,5-Trimethoxyamphetamine (TMA-2; "DOMeO") had been synthesized by Bruckner in 1933, but its psychedelic effects were not described until Shulgin tried the compound and reported its effects in the scientific literature in 1964. Prior to this, 3,4,5-trimethoxyamphetamine (TMA; α-methylmescaline) had been synthesized by Hey in 1947, being found by him to produce euphoria, and was described by Peretz and colleagues in 1955 as clearly producing psychedelic effects. Following his discovery of DOM, Shulgin developed DOET and found that at low doses it was a remarkable "psychic energizer" without producing psychedelic effects at these doses. Dow Chemical Company decided to move forward with clinical trials of DOET as a potential pharmaceutical drug for such purposes. Shulgin and Dow Chemical Company filed a patent for DOET in 1966, although it was not published until 1970. Dow Chemical Company tasked Solomon H. Snyder at Johns Hopkins University with clinically studying DOET. In April 1967, following the banning of LSD in California in 1966, DOM emerged as a street drug and legal LSD alternative with the name "STP" (allegedly short for "Serenity, Tranquility, and Peace") in the Haight-Ashbury district in San Francisco.
Uranium-238 is predominantly an alpha emitter, decaying to thorium-234. It ultimately decays through the uranium series, which has 18 members, into lead-206. Uranium-238 is not fissile, but is a fertile isotope, because after neutron activation it can be converted to plutonium-239, another fissile isotope. Indeed, the 238U nucleus can absorb one neutron to produce the radioactive isotope uranium-239. 239U decays by beta emission to neptunium-239, also a beta-emitter, that decays in its turn, within a few days into plutonium-239. 239Pu was used as fissile material in the first atomic bomb detonated in the "Trinity test" on 16 July 1945 in New Mexico. Uranium-235 has a half-life of about 7.04×108 years; it is the next most stable uranium isotope after 238U and is also predominantly an alpha emitter, decaying to thorium-231. Uranium-235 is important for both nuclear reactors and nuclear weapons, because it is the only uranium isotope existing in nature on Earth in significant amounts that is fissile. This means that it can be split into two or three fragments (fission products) by thermal neutrons. The decay chain of 235U, which is called the actinium series, has 15 members and eventually decays into lead-207. The constant rates of decay in these decay series makes the comparison of the ratios of parent to daughter elements useful in radiometric dating. Uranium-236 has a half-life of 2.342×107 years and is not found in significant quantities in nature.
=== Angiogenesis === The formation of new blood vessels is essential for tumor survival and expansion. Intracrines like VEGF and angiogenin regulate angiogenesis within tumor cells and surrounding endothelial cells. Inhibiting intracrine trafficking of angiogenin to the nucleus has been shown to blunt cancer cell proliferation, making this an emerging therapeutic target.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.